NYSE:CVD - Covance Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$107.07
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Covance Inc. is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services. The early development services include lead optimization services, preclinical services and clinical pharmacology services. The late-stage development services include central laboratory, Phase II-IV clinical development, and market access services.

Receive CVD News and Ratings via Email

Sign-up to receive the latest news and ratings for CVD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry N/A
Sub-IndustryLife Sciences Tools & Services
SectorN/A
Current SymbolNYSE:CVD
Previous Symbol
CUSIP22281610
Phone+1-609-4524440

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Covance (NYSE:CVD) Frequently Asked Questions

What is Covance's stock symbol?

Covance trades on the New York Stock Exchange (NYSE) under the ticker symbol "CVD."

How were Covance's earnings last quarter?

Covance Inc. (NYSE:CVD) released its earnings results on Wednesday, February, 4th. The healthcare company reported $0.97 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $0.97. The healthcare company had revenue of $634 million for the quarter, compared to analyst estimates of $631.30 million. View Covance's Earnings History.

Has Covance been receiving favorable news coverage?

News headlines about CVD stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Covance earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the healthcare company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.

How do I buy shares of Covance?

Shares of CVD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Covance's official website?

The official website for Covance is http://www.covance.com.

How can I contact Covance?

Covance's mailing address is 210 Carnegie Ctr, PRINCETON, NJ 08540-6233, United States. The healthcare company can be reached via phone at +1-609-4524440.


MarketBeat Community Rating for Covance (NYSE CVD)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  242 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about Covance and other stocks. Vote "Outperform" if you believe CVD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by MarketBeat.com Staff

Featured Article: Return on Equity (ROE)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel